Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 3b/4 clinical study titled ‘SWITCH-UP’ to evaluate the efficacy and safety of upadacitinib in adult participants with moderate-to-severe atopic dermatitis who have shown inadequate response to dupilumab. This study aims to provide critical data on the effectiveness of upadacitinib, an approved drug for atopic dermatitis, in improving patient outcomes.
The study tests upadacitinib, an oral tablet, and dupilumab, a subcutaneous injection, to determine their effectiveness in treating atopic dermatitis. The goal is to assess whether upadacitinib can offer a better therapeutic alternative for patients who do not respond well to dupilumab.
Participants are randomly assigned to receive either upadacitinib or dupilumab in an open-label, sequential intervention model. The primary purpose of the study is treatment, with no masking involved in the process.
The study began on June 12, 2024, with an estimated primary completion date not yet disclosed. The last update was submitted on August 19, 2025, indicating ongoing recruitment and data collection.
This study could significantly impact AbbVie’s stock performance by potentially expanding the market for upadacitinib if successful. It may also influence investor sentiment positively, given the competitive landscape in the atopic dermatitis treatment market.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.